Oxandia Limited investment portfolio

Allosterica provides the FastHDX hydrogen‑deuterium exchange LC‑MS/MS platform that maps remote allosteric binding sites on soluble proteins to generate early allosteric hits for drug discovery, especially for G‑protein‑coupled receptor modulators. Its services target pharmaceutical and biotechnology companies developing selective therapeutic candidates.

GliaGenesis applies AI‑driven, multi‑omics drug discovery to identify small‑molecule therapies that promote neural regeneration and glial restoration for neuropsychiatric and neurodegenerative disorders. It conducts pre‑clinical research in rodent models and offers computational analysis services for neuroscience data.